Publications by authors named "Nitesh Dave"

Protein mannosyltransferases (PMTs) catalyze the O-mannosylation of serine and threonine residues of proteins in the endoplasmic reticulum. The five PMT genes coding for protein mannosyltransferases, designated as PMT1, 2, 4, 5 and 6, were identified from Pichia pastoris genome based on the homology to PMT genes in Saccharomyces cerevisiae genome, which has seven PMT genes. The homologues of S.

View Article and Find Full Text PDF

Bio-catalytic in vitro multistep reactions can be combined in a single step in one pot by optimizing multistep reactions under identical reaction condition. Using this analogy, the process of making PEGylated insulin, IN-105, was simplified. Instead of taking the purified active insulin bulk powder as the starting material for the conjugation step, an insulin process intermediate, partially purified insulin ester, was taken as starting material.

View Article and Find Full Text PDF
Article Synopsis
  • Insulin was modified for oral use by attaching a short-chain methoxy polyethylene glycol (mPEG) to a specific amino acid, improving its bioavailability.
  • The conjugation process produced a mix of insulin derivatives, with the desired product (IN-105) being favored by optimizing reaction conditions such as pH and salt concentrations.
  • The final product was purified, characterized, and shown to effectively lower glucose levels in Type 2 diabetes patients, demonstrating its biological activity.
View Article and Find Full Text PDF

A kinetic study of atosiban was conducted following repeated intravenous administration in Wistar rats. Sample analysis was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) following full validation of an in-house method. Eptifibatide, a cyclic peptide, was used as an internal standard (IS).

View Article and Find Full Text PDF

Oral delivery of insulin is convenient and physiologically desirable in the treatment of diabetes. However, this route of administration has presented substantial challenges as insulin is degraded enzymatically in the gut, resulting in low bioavailability. We have developed a conjugated insulin product (IN-105) that has high bioavailability and is currently undergoing clinical trials for the treatment of diabetes.

View Article and Find Full Text PDF